Singapore markets closed

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.61+0.26 (+2.78%)
At close: 04:00PM EDT
9.61 0.00 (0.00%)
After hours: 05:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 726.72M
Enterprise value 883.00M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)2.61
Price/book (mrq)N/A
Enterprise value/revenue 3.20
Enterprise value/EBITDA -4.42

Trading information

Stock price history

Beta (5Y monthly) 1.06
52-week change 3-39.22%
S&P500 52-week change 3-16.62%
52-week high 319.32
52-week low 35.60
50-day moving average 310.63
200-day moving average 310.90

Share statistics

Avg vol (3-month) 31.11M
Avg vol (10-day) 3877.52k
Shares outstanding 577.72M
Implied shares outstanding 6N/A
Float 869.03M
% held by insiders 11.89%
% held by institutions 1106.47%
Shares short (14 Sept 2022) 49.4M
Short ratio (14 Sept 2022) 48.68
Short % of float (14 Sept 2022) 415.30%
Short % of shares outstanding (14 Sept 2022) 412.10%
Shares short (prior month 14 Aug 2022) 410.4M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin -83.47%
Operating margin (ttm)-71.44%

Management effectiveness

Return on assets (ttm)-19.18%
Return on equity (ttm)-345.06%

Income statement

Revenue (ttm)276.14M
Revenue per share (ttm)3.58
Quarterly revenue growth (yoy)-31.40%
Gross profit (ttm)250.27M
EBITDA -193.89M
Net income avi to common (ttm)-230.49M
Diluted EPS (ttm)-2.75
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)275.48M
Total cash per share (mrq)3.54
Total debt (mrq)431.76M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.17
Book value per share (mrq)-0.29

Cash flow statement

Operating cash flow (ttm)-142.69M
Levered free cash flow (ttm)-111.17M